PTSM: Pharmaceutical Technology Sourcing and Management
In a pilot program, Johnson & Johnson Supply Chain and AmerisourceBergen demonstrated how data can be transferred between two partners.
In 2016, the pharmaceutical manufacturer Johnson & Johnson Supply Chain (JJSC) and the distributor AmerisourceBergen launched a four-week pilot program to test GS1’s EPCIS standards and to see how effectively data could be transferred between the two partners. JJSC has been working on serialization for some time, and began shipping serialized product back in 2012, so both companies were fully connected, in terms of their IT, and they could try this approach with serialized product. The test simulated the real-world supply chain.
A DataMatrix barcode was applied containing a serialized global trade item number (GTIN), batch and lot number, and expiration data for each sellable unit (whether bottle, vial, or blister), and the units were packed into cases and loaded onto pallets, while downstream vision systems and scanners read the barcode to capture all the information. EPCIS recorded events associated with the GTIN, so that AmerisourceBergen could confirm receipt of each item sent by JJSC, automatically.
Results showed not only the viability of this approach, but its potential power. “It’s like electronic data interchange (EDI) on steroids,” says Mike Rose, vice-president, supply chain visibility at JJSC. “Over time, supply chain partners will be able to exchange a lot of critical data for additional value,” he says. The pilot ensured that all processes, from plant to warehouse and distribution channel to docks, were tracked. “It forced us to test all processes along with way. We got confirmation from our partner that everything fed back to them, from plant to distribution center, and that they were receiving relevant process data.” Rose expects to see return on investment in terms of improved inventory management and transparency in the future. “But for now, our focus remains on the patient first,” he says.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.